Archive | Life Science ETF’s and Mutual Funds

Auxilium (AUXL) Holding Up After Barron’s “Not-So-Great Math”

get orlistat 120 mg without prescription Auxilium (AUXL) shares held up today ($24.85 up 0.65%) after a June 28 article questioned the valuation of the stock. Revenues for the last quarter were $45.5M primarily from its Testim testosterone gel, with a loss of $8.6M.Analysts have high expectations for a recently approved drug Xiaflex for treatment of Dupuytren’s disease and  reduce surgery […]

Continue Reading 0

Supergen(SUPG) in a Rally Mode at $2.43;Reiterate Buy

follow Supergen (SUPG) has been moving up steadily over the past few days since its low in the $2.10+ range this week.SUPG is in the Rayno Life Science Portfolio. The April 15,2010 high was $3.72.The balance sheet is strong with over $100M in cash,Shareholder Equity of $106M and no debt. Market Cap is $147M. Revenue for […]

Continue Reading 0

Rayno Life Science Portfolio Update: Finally a Rally Day

http://viewtific.com/bicycling-in-tranquility-madrid-map/ Any momentum in biotech stocks from ASCO have been eclipsed by bearish, volatile trends overall.  There were some nice moves up today with the Rayno Life Science Portfolio was up 2.67% and all bio ETF’s did well: FBT up 3%,XBI up 3.48%, and IBB up 3.11%. Among the big movers in the Rayno Portfolio were: […]

Continue Reading 0

ASCO: Little Help for Biotech Stocks

Two Big Winners in Bristol Myers Squibb and Celgene The American Society of Oncology Meeting is normally good times for biotech as scientific and clinical developments propel stocks. This year the personalized medicine theme with potential breakthroughs in  targeted therapy for cancer is expected show excellent clinical results. In advance of ASCO Bristol Myers(BMY) presented […]

Continue Reading 0

Cubist (CBST) Pharmaceuticals Up 3% on Heavy Volume

In a nasty market where many indices are down 2.5% or more Cubist bucks the trend up 3% apparently on a Cowen and Co. upgrade from Neutral to Outperform.As of midday trading with a Volume of 2.8M shares the stock is at $22.25 up from $21.5 yesterday. The stock is up this year reaching a […]

Continue Reading 0

Biomarkers Drive Personalized Medicine

Companion Diagnostics Enable More Targeted Therapy At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and diagnostics. This explosive new technology niche, is a nascent paradigm for exploiting breakthroughs in the molecular basis of disease and more targeted […]

Continue Reading 0

Goldman Charge Curbs Enthusiasm for Market Risk

Larger Cap Healthcare Stocks Holding Up Well The SEC charges against Goldman Sachs have taken the MO out of the market with speculative issues down considerably. As of midday trading the Dow is down 1.2%. NASDAQ down 1.5% and the S&P down 1.6%.Stocks are off their lows. Large Cap healthcare and biotech stocks were less […]

Continue Reading 0

Rayno Life Science Portfolio 2010: Biopharmaceuticals

Exelixis (EXEL) added as speculative buy at $3.30 on 9/2/10 Update: Portfolio rebalancing below but we are still in a bearish mode with small cap biotech. The brief rally spurred by a potential buyout rumor by Sanofi last Friday has evaporated with Biogen,Celgene Genzyme and Gilead all down. The IBB is flat for the year. […]

Continue Reading 0

Rayno Life Science Portfolio : Diagnostics and Tools, Quidel and Celera

Quidel (QDEL) was up 7.9% yesterday to $12.13 on volume of 375k shares. This stock is now under review and is a value buy in the $12 range. Quidel bought Diagnostic Hybrids for for $131M in Q1 bringing debt to $83M. Wedbush upgraded the stock on May 27. Celera(CRA) is being added as a buy […]

Continue Reading 0

Immucor(BLUD) Profits Up but Stock Down 8 %

Immucor (BLUD) a global leader in providing instrument-reagent systems to the blood transfusion industry  delivered more than expected financial results for the 3rd Quarter of fiscal 2010 ended February 28. Revenue of $80.5M was up 7% from prior year quarter. Gross margin was 69.2% compared to prior year quarter of 71.4%. Diluted earnings per share […]

Continue Reading 0